File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus

TitlePharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus
Authors
KeywordsDDAVP
Intranasal
Oral diabetes insipidus
Pharmacodynamics
Pharmacokinetics
Issue Date1996
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP
Citation
British Journal Of Clinical Pharmacology, 1996, v. 42 n. 3, p. 379-385 How to Cite?
Abstract1. The pharmacokinetics and pharmacodynamics of intranasal (IN) and oral 1-deamino-8-D-arginine vasopressin (DDAVP) were compared in 10 Chinese adults with central diabetes insipidus previously controlled on IN DDAVP. This was followed by comparison of the acute pharmacodynamics of commonly used oral preparations (containing 100, 200 and 400 μg per tablet) and a 1 year prospective evaluation of the long-term safety and efficacy of oral DDAVP. 2. Following 20 μg IN and 200 μg orally, respective plasma DDAVP concentrations peaked after 45.6 ± 7.3 and 93.3 ± 3.3 (mean ± s.e.mean) min, reaching 24.1 ± 4.7 and 15.1 ± 3.2 pmol l -1 and respective terminal half-lives were 2.2 ± 0.1 and 2.0 ± 0.1 h. Based on the area under the concentration-time-curve, the bioequivalent IN/oral ratio was 1:16. 3. As judged by changes in urine flow rate and osmolality after IN or oral (100, 200 or 400 Gig) DDAVP, antidiuretic activity increased rapidly during the second hour and peaked at 4 h. The antidiuresis duration and magnitude correlated with the oral dose (P < 0.001 and <0.05 respectively), and was least following 100 μg (P<0.01 vs 200 or 400 μg). Increasing the dose from 200 to 400 μg did not increase maximal antidiuretic activity significantly, but there was a trend towards a longer duration of action (P = 0.076). 4. During the 1-year prospective study with oral DDAVP 300-600 μg per day in two to three doses, stable and satisfactory antidiuresis (comparable with that on previous IN therapy) was maintained; tablets were well-tolerated and no side-effect warranted drug withdrawal. 5. These findings suggest that the 100 and 200 μg preparations of oral DDAVP are adequate for the long-term control of central diabetes insipidus in our population, and that the 400 μg preparation may have a role if the frequency of administration is to be reduced.
Persistent Identifierhttp://hdl.handle.net/10722/48973
ISSN
2015 Impact Factor: 3.83
2015 SCImago Journal Rankings: 1.486
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorWat, MSen_HK
dc.contributor.authorChoi, KLen_HK
dc.contributor.authorIp, TPen_HK
dc.contributor.authorPang, RWCen_HK
dc.contributor.authorKumana, CRen_HK
dc.date.accessioned2008-06-12T06:31:08Z-
dc.date.available2008-06-12T06:31:08Z-
dc.date.issued1996en_HK
dc.identifier.citationBritish Journal Of Clinical Pharmacology, 1996, v. 42 n. 3, p. 379-385en_HK
dc.identifier.issn0306-5251en_HK
dc.identifier.urihttp://hdl.handle.net/10722/48973-
dc.description.abstract1. The pharmacokinetics and pharmacodynamics of intranasal (IN) and oral 1-deamino-8-D-arginine vasopressin (DDAVP) were compared in 10 Chinese adults with central diabetes insipidus previously controlled on IN DDAVP. This was followed by comparison of the acute pharmacodynamics of commonly used oral preparations (containing 100, 200 and 400 μg per tablet) and a 1 year prospective evaluation of the long-term safety and efficacy of oral DDAVP. 2. Following 20 μg IN and 200 μg orally, respective plasma DDAVP concentrations peaked after 45.6 ± 7.3 and 93.3 ± 3.3 (mean ± s.e.mean) min, reaching 24.1 ± 4.7 and 15.1 ± 3.2 pmol l -1 and respective terminal half-lives were 2.2 ± 0.1 and 2.0 ± 0.1 h. Based on the area under the concentration-time-curve, the bioequivalent IN/oral ratio was 1:16. 3. As judged by changes in urine flow rate and osmolality after IN or oral (100, 200 or 400 Gig) DDAVP, antidiuretic activity increased rapidly during the second hour and peaked at 4 h. The antidiuresis duration and magnitude correlated with the oral dose (P < 0.001 and <0.05 respectively), and was least following 100 μg (P<0.01 vs 200 or 400 μg). Increasing the dose from 200 to 400 μg did not increase maximal antidiuretic activity significantly, but there was a trend towards a longer duration of action (P = 0.076). 4. During the 1-year prospective study with oral DDAVP 300-600 μg per day in two to three doses, stable and satisfactory antidiuresis (comparable with that on previous IN therapy) was maintained; tablets were well-tolerated and no side-effect warranted drug withdrawal. 5. These findings suggest that the 100 and 200 μg preparations of oral DDAVP are adequate for the long-term control of central diabetes insipidus in our population, and that the 400 μg preparation may have a role if the frequency of administration is to be reduced.en_HK
dc.format.extent388 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCPen_HK
dc.relation.ispartofBritish Journal of Clinical Pharmacologyen_HK
dc.rightsBritish Journal of Clinical Pharmacology. Copyright © Blackwell Publishing Ltd.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsThe definitive version is available at www.blackwell-synergy.comen_HK
dc.subjectDDAVPen_HK
dc.subjectIntranasalen_HK
dc.subjectOral diabetes insipidusen_HK
dc.subjectPharmacodynamicsen_HK
dc.subjectPharmacokineticsen_HK
dc.titlePharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0306-5251&volume=42&issue=3&spage=379&epage=385&date=1996&atitle=Pharmacokinetics,+pharmacodynamics,+long-term+efficacy+and+safety+of+oral+1-deamino-8-D-arginine+vasopressin+in+adult+patients+with+central+diabetes+insipidusen_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailPang, RWC: robertap@hkucc.hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1046/j.1365-2125.1996.39914.xen_HK
dc.identifier.pmid8877030-
dc.identifier.pmcidPMC2042683en_HK
dc.identifier.scopuseid_2-s2.0-0029793247en_HK
dc.identifier.hkuros37404-
dc.identifier.hkuros22853-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029793247&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume42en_HK
dc.identifier.issue3en_HK
dc.identifier.spage379en_HK
dc.identifier.epage385en_HK
dc.identifier.isiWOS:A1996VF23500014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridWat, MS=6603247639en_HK
dc.identifier.scopusauthoridChoi, KL=36985280300en_HK
dc.identifier.scopusauthoridIp, TP=7003866522en_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK
dc.identifier.scopusauthoridKumana, CR=7005112381en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats